NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

SNY

Sanofi ADR

Apr 17 • 04:00PM ET

50.90

Dollar change +0.34
Percentage change 0.67	%

Healthcare • Drug Manufacturers - General • France • NASD

Peers: NVS PFE MRK GSK BMY LLY AZN JNJ ABBV AMGN

| Held by: PVAL GCOW FVD PPH PID AVDE APIE QQQJ PLDR BUSA

Scroll to Statements

Index	-	P/E	21.26	EPS (ttm)	2.39	Insider Own	0.00%	Shs Outstand	2.61B	Perf Week	2.50%
Market Cap	124.61B	Forward P/E	10.25	EPS next Y	4.96	Insider Trans	-	Shs Float	2.45B	Perf Month	-13.14%
Income	6.02B	PEG	1.69	EPS next Q	0.92	Inst Own	10.82%	Short Float	0.16%	Perf Quarter	0.32%
Sales	44.44B	P/S	2.80	EPS this Y	21.23%	Inst Trans	-0.21%	Short Ratio	1.41	Perf Half Y	-6.73%
Book/sh	32.01	P/B	1.59	EPS next Y	10.26%	ROA	4.29%	Short Interest	4.00M	Perf Year	11.14%
Cash/sh	3.20	P/C	15.93	EPS next 5Y	12.58%	ROE	7.34%	52W Range	45.22 - 60.12	Perf YTD	5.54%
Dividend Est.	2.27 (4.46%)	P/FCF	15.67	EPS past 5Y	13.05%	ROI	6.39%	52W High	-15.33%	Beta	0.57
Dividend TTM	2.04 (4.00%)	Quick Ratio	0.73	Sales past 5Y	2.13%	Gross Margin	63.49%	52W Low	12.56%	ATR (14)	1.55
Dividend Ex-Date	May 09, 2025	Current Ratio	1.08	EPS Y/Y TTM	2.96%	Oper. Margin	23.14%	RSI (14)	39.51	Volatility	2.31% 2.63%
Employees	84587	Debt/Eq	0.23	Sales Y/Y TTM	-4.57%	Profit Margin	13.54%	Recom	1.64	Target Price	65.46
Option/Short	Yes / Yes	LT Debt/Eq	0.17	EPS Q/Q	-	Payout	66.96%	Rel Volume	1.01	Prev Close	50.56
Sales Surprise	3.35%	EPS Surprise	3.11%	Sales Q/Q	-	Earnings	Apr 24 BMO	Avg Volume	2.84M	Price	50.90
SMA20	-4.03%	SMA50	-7.23%	SMA200	-3.77%	Trades		Volume	2,856,361	Change	0.67%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-25	Initiated	Exane BNP Paribas	Outperform	$65
Mar-21-25	Initiated	Goldman	Neutral	$65
Jan-30-25	Upgrade	Deutsche Bank	Sell → Hold
Jul-26-24	Reiterated	Argus	Buy	$55 → $60
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$55
Jan-16-24	Resumed	UBS	Buy
Dec-05-23	Downgrade	JP Morgan	Overweight → Neutral
Oct-30-23	Downgrade	Stifel	Buy → Hold
Sep-06-23	Upgrade	Berenberg	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-28-23	Downgrade	Deutsche Bank	Hold → Sell
Mar-27-23	Upgrade	Barclays	Equal Weight → Overweight
Dec-13-22	Resumed	Morgan Stanley	Overweight
Aug-12-22	Upgrade	Deutsche Bank	Sell → Hold
Aug-09-22	Downgrade	UBS	Buy → Neutral
May-23-22	Initiated	SVB Leerink	Outperform
Sep-27-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-15-21	Initiated	Deutsche Bank	Sell
Sep-29-20	Initiated	Berenberg	Hold
Mar-17-20	Upgrade	Barclays	Underweight → Equal Weight

Show Previous Ratings

Apr-18-25 11:15AM	Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria (GlobeNewswire)
11:15AM	Dupixent (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU) (GlobeNewswire)
09:13AM	Sanofi, Regeneron win FDA nod for Dupixent in chronic hives (BioPharma Dive)
Apr-17-25 05:07PM	Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential (Seeking Alpha)
09:15AM	Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback (Zacks)
07:19AM	Loading…
07:19AM	Sanofi licenses immune disease drugs from startup Earendil (BioPharma Dive)
05:54AM	Glycomine secures $115m funding for Phase IIb trial of rare disease drug (Pharmaceutical Business Review)
Apr-16-25 11:47AM	Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications (Zacks)
06:28AM	Dodge & Cox Global Stock Fund Q1 2025 Shareholder Letter (Seeking Alpha)
05:55AM	Dodge & Cox Stock Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-15-25 08:00AM	Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement (PR Newswire)
05:39AM	Tariff wars to hit popular US-made drugs in China, regulator data shows (Reuters)
01:00AM	Press Release: Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD (GlobeNewswire)
Apr-11-25 09:07AM	Why You Shouldn't Bet Against Sanofi (SNY) Stock (Zacks)
08:39AM	Novavax: Regulatory Uncertainty Creates Risk And Opportunity For Beaten-Down Vaccine Developer (Seeking Alpha)
10:39AM	Loading…
Apr-10-25 10:39AM	Harbor Dividend Growth Leaders ETF Q4 2024 Commentary (Seeking Alpha)
Apr-09-25 12:03PM	AAN 2025: Sanofis tolebrutinib likely to be first BTK inhibitor for the treatment of MS (Clinical Trials Arena)
12:03PM	Top Stock Movers Now: Delta, Apple, Eli Lilly, and More (Investopedia)
10:28AM	Pharma Stocks Sink as Trump Says 'Major' Tariffs Coming to Industry (Investopedia)
09:51AM	Novo Nordisk, AbbVie Stocks Slide After Trump Vows Pharma Tariffs (The Wall Street Journal)
08:17AM	Novo Nordisk, AbbVie, Other Stocks Tumble After Trump Threatens Pharma Tariffs (The Wall Street Journal)
06:17AM	Pharma Stocks Drop After Trump Threatens Tariffs on Medicines (The Wall Street Journal)
05:40AM	Trump Says Pharmaceutical Tariffs Coming Very Shortly (Bloomberg)
Apr-08-25 01:11PM	Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis (GlobeNewswire)
Apr-07-25 09:08AM	Syndax Pharmaceuticals: Down But Not Out (Seeking Alpha)
Apr-06-25 04:46AM	All the Stocks Warren Buffett Bought in the Last 2 Recessions: Are They Smart Picks Now? (Motley Fool)
02:36AM	Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow (Seeking Alpha)
Apr-05-25 03:00PM	Tariffs Stoke Fears That Hung Debt Will Return (Bloomberg)
Apr-04-25 09:46AM	Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure (Zacks)
04:51AM	FDA awards ODD status to Sanofis rilzabrutinib for two rare conditions (Pharmaceutical Technology)
02:08PM	Loading…
Apr-03-25 02:08PM	Sanofi: Information concerning the total number of voting rights and shares - February 2025 (GlobeNewswire)
11:27AM	SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases (Zacks)
09:08AM	NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program (Zacks)
01:00AM	Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines (GlobeNewswire)
Apr-02-25 09:20AM	Sanofi: Qfitlia Approval A Bright Spot As Landscape Darkens For European Pharma (Seeking Alpha)
08:20AM	Leqembis EU review drags on; Sanofi gets a new development head (BioPharma Dive)
Apr-01-25 12:42PM	Is Sanofi (SNY)the Best Gene-Editing Stock to Buy? (Insider Monkey)
09:44AM	SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States (Zacks)
05:27AM	Japan's MHLW authorises Regeneron and Sanofi's Dupixent for COPD (Pharmaceutical Business Review)
Mar-31-25 10:55AM	Sanofis Qfitlia approved by FDA as first haemophilia therapy for all patients (Pharmaceutical Technology)
08:28AM	FDA Approves Sanofi's Hemophilia Drug (Benzinga)
06:20AM	Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now? (Zacks)
Mar-28-25 04:07PM	Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors (GlobeNewswire)
02:27PM	US FDA approves Sanofi's bleeding disorder therapy (Reuters)
01:39PM	FDA approves first-of-its-kind RNA drug for hemophilia (BioPharma Dive)
09:44AM	AbbVie Vs. Sanofi: Which Is The Better Investment Right Now (Seeking Alpha)
09:29AM	Corvus Pharmaceuticals: Now At Cruising Altitude (Seeking Alpha)
03:01AM	Innate Pharma SA (IPHA) (FY 2024) Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
02:00AM	Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD (GlobeNewswire)
02:00AM	Dupixent (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD) (GlobeNewswire)
01:00AM	ClearBridge International Value ADR Portfolios Q4 2024 Commentary (Seeking Alpha)
Mar-27-25 05:37PM	Analyst Report: Sanofi (Morningstar Research)
11:34AM	Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive (Zacks)
11:30AM	U.S. to end funding for child vaccines in developing countries, NY Times reports (TipRanks)
10:20AM	ClearBridge International Value Fund Q4 2024 Commentary (SeekingAlpha)
02:00AM	Sanofis chief digital officer says remote work means employees lose the serendipity needed to innovate (Fortune)
Mar-26-25 08:57PM	Analyst Report: Sanofi (Morningstar Research)
11:53AM	Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag (Zacks)
08:15AM	FDA fast tracks Sanofis mRNA vaccine for chlamydia (Pharmaceutical Technology)
02:06AM	FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised) (Zacks)
02:00AM	Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA (GlobeNewswire)
Mar-25-25 07:56AM	FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Zacks)
02:00AM	Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis (GlobeNewswire)
Mar-24-25 11:50AM	Ariel International Fund And Ariel Global Fund Q4 2024 Commentary (SeekingAlpha)
10:15AM	Ariel International And Global Funds Q4 2024 Commentary (SeekingAlpha)
10:15AM	Ariel International And Global Fudns Q4 2024 Commentary (SeekingAlpha)
02:30AM	Press Release: Availability of the Q1 2025 Aide m moire (GlobeNewswire)
Mar-22-25 01:40AM	The Davenport Balanced Income Fund Q4 2024 Commentary (SeekingAlpha)
Mar-21-25 12:26PM	Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals (Zacks)
12:20PM	The Davenport Value & Income Fund Q4 2024 Commentary (SeekingAlpha)
09:32AM	FedEx downgraded, Adobe upgraded: Wall Street's top analyst calls (The Fly)
07:21AM	Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy (SeekingAlpha)
05:55AM	Banks Launch 7.45 Billion Debt Sale for Sanofi Unit Buyout (Bloomberg)
Mar-20-25 10:35PM	BlackRock Sustainable U.S. Value Equity Fund Q4 2024 Commentary (SeekingAlpha)
05:49PM	Former Texas congressman Burgess eyed as CDC director nominee - report (SeekingAlpha)
02:11PM	U.S. boosts bird flu response with another $100M in funds (SeekingAlpha)
01:34PM	Sanofi outlays $1.9bn to purchase Dren Bios bispecific antibody (Pharmaceutical Technology)
12:30PM	Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug (Zacks)
09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
07:20AM	Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease (BioPharma Dive)
06:52AM	Wall Street Breakfast Podcast: March Madness Heats Up, Bets Roll In (SeekingAlpha)
04:43AM	Sanofi strikes autoimmune drug deal for up to $1.9B (SeekingAlpha)
02:29AM	Sanofi to acquire Dren Bio's immunology unit (Reuters)
02:00AM	Press Release: Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline (GlobeNewswire)
Mar-19-25 05:57AM	Banks Aim to Sell 8.65 Billion Sanofi Buyout Debt Next Week (Bloomberg)
Mar-14-25 02:18PM	Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season (PR Newswire)
Mar-08-25 01:00PM	Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD (GlobeNewswire)
01:00PM	Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD (GlobeNewswire)
11:21AM	CDC plans study into potential vaccines, autism connections, Reuters reports (TipRanks)
Mar-05-25 08:25PM	Analyst Report: Sanofi (Morningstar Research)
12:10PM	Press release: Sanofi successfully prices EUR 1.5 billion of bond issue (GlobeNewswire)
09:45AM	What Trump's next batch of tariffs could mean for pharma industry (Yahoo Finance Video)
02:01AM	Euroapi SA (EAPIF) (FY 2024) Earnings Call Highlights: Navigating Challenges and Embracing ... (GuruFocus.com)
Mar-01-25 02:40PM	Is Sanofi (SNY) The Best Immunology Stock To Buy Now? (Insider Monkey)
Feb-28-25 11:00AM	Q4 2024 Cytokinetics Inc Earnings Call (Thomson Reuters StreetEvents)
02:15AM	Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ... (GuruFocus.com)
02:11AM	Novavax Inc (NVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial ... (GuruFocus.com)
Feb-27-25 01:30PM	Q4 2024 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
09:46AM	Novavax reports large quarterly revenue declines, rethinks its strategic direction (Yahoo Finance)
09:25AM	Novavax shares up on fourth quarter earnings beat (Investing.com)

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNY

Sanofi ADR

Upgrade your FINVIZ experience